Business UpdateJun 29, 2026, 04:12 PM
Elite Pharma Launches 6 Products (2024-2026); Impairs Loxapine & Patent
AI Summary
Elite Pharmaceuticals, Inc. announced the commercial launch of six new generic pharmaceutical products between August 2024 and April 2026, including Methotrexate Sodium, APAP Codeine, APAP Hydrocodone, Lisdexamfetamine Dimesylate, Oxy APAP, and Methadone Tablets. Several of these products were acquired through an asset purchase agreement with Nostrum Laboratories Inc. Concurrently, the company recognized an impairment of Loxapine Capsules and fully impaired capitalized costs for an abuse-deterrent opioid patent during the fiscal year ended March 31, 2026, and paused the development of its SequestOx™ abuse-deterrent opioid candidate.
Key Highlights
- Launched Methotrexate Sodium tablets commercially in August 2024.
- Launched APAP Codeine Tablets and APAP Hydrocodone Tablets in October and December 2024, respectively, acquired via Nostrum Asset Purchase Agreement.
- Launched Lisdexamfetamine Dimesylate capsules in December 2024.
- Launched Oxy APAP Tablets in April 2025 and Methadone Tablets in April 2026, both acquired via Nostrum Asset Purchase Agreement.
- Recognized an impairment of Loxapine Capsules during the fiscal year ended March 31, 2026.
- Fully impaired capitalized costs for an abuse-deterrent opioid patent in Fiscal 2026 due to expiration before marketing authorization.
- Paused development of SequestOx™, an abuse-deterrent opioid candidate, due to prohibitive costs and uncertain commercial viability.
- First shipment of Amphetamine IR Tablets to Dexcel Ltd. for the Israeli market occurred in July 2025.
Price Impact
More from ELTP